SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
1 finding from 1 review
Hospitalisations, number of participants with 1 or more exacerbations · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
Tiotropium probably leads to lower patients with 1 or more exacerbations compared with long‐acting beta‐agonists (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
It is very uncertain whether tiotropium changes mortality (all‐cause) compared with long‐acting beta‐agonists (very low certainty).
1 finding from 1 review
Cost‐effectiveness · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
1 finding from 1 review
no estimate extracted
6 participants
Low
Intervention not reported
Peak exercise capacity: Power (W) · people with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Peak exercise capacity: Peak oxygen consumption (VO2peak) (L/min) · people with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Peak exercise test: Lactate threshold (L/min) · people with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Peak exercise test: Isowork minute ventilation (VE) (L) · people with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Peak exercise test: Isowork dyspnoea score · people with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Exercise tolerance: Endurance time (min) · people with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Functional exercise capacity: Six‐minute walk distance (m) · people with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Health‐related Quality of Life: Dyspnoea domain of the CRQ · people with chronic obstructive pulmonary disease
1 finding from 1 review
Pruritus · health problem or population
1 finding from 1 review
Quality of life ‐ not measured · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not reported · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · health problem or population
Summary of findings table ‐ GABA‐analogues showed no clear difference in risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
FEV1 · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Z score FVC · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
HRCT score · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review